Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: J Immunol. 2009 May 15;182(10):6600–6609. doi: 10.4049/jimmunol.0801214

FIGURE 2.

FIGURE 2

The effect of clinically relevant drugs on NKG2D ligand expression. A, Cisplatin and bleomycin do not induce NKG2D ligand expression. FaDu HNSCC cells were untreated (gray shading) or were treated for 16 h with the indicated drug (dashed line) and stained with anti-ULBP1 mAb. Cisplatin and bleomycin treatment did not change expression of MHC class I, MICA, MICB, or ULBP2−4 (not shown). B, Bortezomib induces cell surface ULBP1 expression. FaDu cells were treated with DMSO or bortezomib for 16 h and stained with nonspecific mouse IgG (speckled and solid histograms representing control and bortezomib-treated cells) and with the indicated anti-NKG2D ligand mAb (gray and hatched histograms representing control and bortezomib-treated cells). For A and B, flow cytometry results are presented on a log scale. C, Bortezomib selectively induces ULBP1 mRNA expression. FaDu cells were treated with DMSO solvent or with bortezomib for 5 h and NKG2D ligand RNA was measured. Shown are means and 95% confidence limits of three independent experiments.